TSAAI 2017 Annual Meeting

Pigeon Forge, TN US
July 28, 2017 to July 30, 2017

Didactic lectures allowing speakers to provide evidence based medical recommendations, updates and expert opinion in an efficient manner.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology (TSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  7 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from AstraZeneca, Shire and Teva.

Target Audience

Practicing allergists, fellows in training, primary care physicians and allied healthcare providers in the field of allergy.

Learning Objectives

        At the conclusion of this activity, participants should be able to:

  • Discuss how the terms “allergies” and “sinus” have multiple meanings to patients and physicians
  • Evaluate and treat patients with candidiasis
  • Explain the criteria for hypereosinophilia and hyperosinophilic syndrome
  • Recognize asthma patients who require monoclonal antibody treatments
  • Distinguish the difference between e-cigarettes and tobacco cigarettes in contributing to asthma
  • Summarize government interventions in medical care which may impact allergy practice
Additional information
Disclosure: 

Disclosures

TSAAI 2017 Annual Meeting

July 28 – 30, 2017 ~ Pigeon Forge, TN

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Mark Ballow, MD

Advisory Council: CSL Behring, Grifols, Shire.  Speaker:  Shire.  Research Grant:  CSL Behring.  Consultant: CSL Behring.  Honorarium: DSMB, Promedic. Consultant: UpToDate. 

Michael Blaiss, MD

Consultant: PMD Healthcare, Pfizer, Stallergenes, JDP Therapeutics, ALK, RxBandz.

Patricia Fulkerson, MD, PhD

Consultant: Genentech.

S. Bobo Tanner, MD

Speaker/Honorarium:  BMS, Pfizer.  Contracted Research: GSK .

*Tidence Prince, MD

Speaker/Honorarium: Meda, Novartis, AstraZeneca, Teva, CSL Behring, Shire. Advisory Board Member: CSL Behring, AstraZeneca, Shire.  Consultant: Shire. 

The following have no relevant financial relationships to disclose:

William K. Dolen, MD, Speaker

John Fahrenholz, MD, Speaker

Reba Green, Meeting Coordinator

Speaker

*Program Chair and Physician Planner

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
07/28/2017
Course expires: 
07/30/2019
Event starts: 
07/28/2017 - 4:00pm
Event ends: 
07/30/2017 - 11:30am
Cost:
$0.00
Rating: 
0
Dollywood DreamMore
2525 DreamMore Way
Pigeon Forge, TN 37863
United States
+1 (865) 365-1900

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma and Immunology (TSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of  7 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from AstraZeneca, Shire and Teva.

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance

Accreditation Period

Course opens: 
07/28/2017
Course expires: 
07/30/2019

Price

Cost:
$0.00
Please login or create an account to take this course.